Development of Systemic Inflammatory Polyarthritis After Zygapophyseal Joint Injection With Hylan G-F 20 (Synvisc-One)

Denizen Kocak, Thiru Annaswamy, Sharon Chong, Rashmi Arora

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Hylan G-F 20 (Synvisc-One) is a hyaluronic acid derivative used for viscosupplementation of synovial fluid in osteoarthritic joints. Injection of hylan G-F 20 is Federal Drug Administration approved for use in knee osteoarthritis and is generally well tolerated with few reported adverse effects, the most common being local pain or swelling. We present the case of a 72-year-old man with bilateral, diffuse, joint pain and swelling with elevated inflammatory markers suggestive of a systemic inflammatory polyarthropathy that developed acutely 2 days after lumbar zygapophyseal joint injection with hylan G-F 20. Systemic effects after hylan G-F 20 injection have not been well documented, and this is the first reported case of systemic inflammatory polyarthritis after injection, to our knowledge. Further research is needed to better establish the safety and efficacy of lumbar zygapophyseal joint injections with hylan G-F 20.

Original languageEnglish (US)
Pages (from-to)147-149
Number of pages3
JournalAmerican Journal of Physical Medicine and Rehabilitation
Volume97
Issue number2
DOIs
StatePublished - Feb 1 2018

Keywords

  • Adverse Reaction
  • Hylan G-F 20
  • Synvisc
  • Systemic Polyarthritis

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation

Fingerprint Dive into the research topics of 'Development of Systemic Inflammatory Polyarthritis After Zygapophyseal Joint Injection With Hylan G-F 20 (Synvisc-One)'. Together they form a unique fingerprint.

Cite this